StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.43−0.02 (-3.39%)

Close on Nov 18, 2026Market cap $249.06KP/E –Yield –

Virax Biolabs revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2026 it was $12.42K, up 96.2% from the year before. The highest annual figure on record is $156.42K in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2026Mar 31, 2026$12.42K+96.2%
FY2025Mar 31, 2025$6.33K-96.0%
FY2024Mar 31, 2024$156.42K+1727.1%
FY2023Mar 31, 2023$8.56K–
FY2022Mar 31, 2022$0-100.0%
FY2021Mar 31, 2021$123.82K–

More Virax Biolabs figures

See a number that looks wrong?